The Impact of Nonalcoholic Fatty Liver Disease on the Outcomes of Coronavirus Disease 2019 Infection

Asemota, Joseph; Aduli, Farshad

doi:10.1002/cld.1169

Cited by 5 publications

(6 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, no difference in mortality was observed in comparison to non-NAFLD patients[ 61 ]. Similar findings have also been reported in other studies[ 60 , 62 , 63 ]. However, a single-center study from India reported a nonsignificant difference in hospital stay and mortality in COVID-19 patients with or without NAFLD[ 64 ].…”

Section: Chronic Liver Diseasesupporting

confidence: 93%

“…The range may be an overestimate, as most of the studies were concentrated on hospitalized patients[ 59 ]. NAFLD (recently renamed metabolic dysfunction-associated fatty liver disease) is associated with factors like diabetes and obesity, which are known to aggravate COVID-19 severity[ 60 ]. An electronic health records-based study reported that CLD patients have an increased risk of acquiring COVID-19 with the highest odds in patients with NAFLD (adjusted OR: 13.11), nonalcoholic cirrhosis (adjusted OR: 11.5) and chronic hepatitis C (adjusted OR: 8.7)[ 41 ].…”

Section: Chronic Liver Diseasementioning

confidence: 99%

See 1 more Smart Citation

Hepatic manifestations of coronavirus disease 2019 infection: Clinical and laboratory perspective

Hanif¹,

Majid²,

Ahmed³

et al. 2022

World J Virol

View full text Add to dashboard Cite

The novel coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2, has become a global challenge of unprecedented nature since December 2019. Although most patients with COVID-19 exhibit mild clinical manifestations and upper respiratory tract involvement, in approximately 5%-10% of patients, the disease is severe and involves multiple organs, leading to multi-organ dysfunction and failure. The liver and gastrointestinal tract are also frequently involved in COVID-19. In the context of liver involvement in patients with COVID-19, many key aspects need to be addressed in both native and transplanted organs. This review focuses on the clinical presentations and laboratory abnormalities of liver function tests in patients with COVID-19 with no prior liver disease, patients with pre-existing liver diseases and liver transplant recipients. A brief overview of the history of COVID-19 and etiopathogenesis of the liver injury will also be described as a prelude to better understanding the above aspects.

show abstract

Section: Chronic Liver Diseasesupporting

confidence: 93%

Section: Chronic Liver Diseasementioning

confidence: 99%

Hepatic manifestations of coronavirus disease 2019 infection: Clinical and laboratory perspective

Hanif¹,

Majid²,

Ahmed³

et al. 2022

World J Virol

View full text Add to dashboard Cite

show abstract

“…COVID-19 enters the cholangiocytes through ACE2-R and causes direct damage with liver enzyme alteration, including albumin, GGT, ALT, and AST [ 95 , 96 , 97 ]. Moreover, the cytokine storm activated in COVID-19 affects the liver directly.…”

Section: Covid-19 and Nafld (Non-alcoholic Fatty Liver Disease)mentioning

confidence: 99%

“…TNF- α , a pro-inflammatory protein, is produced by adipose tissue and liver macrophages and modifies the immune response in patients with NAFLD. This process has consequences for M1 macrophages, which are suppressed, while M2 macrophages have an intense activation [ 95 , 96 , 97 ]. Taking this statement into account, it is necessary to identify a targeted treatment to reduce FLI [ 95 , 96 , 97 ].…”

Section: Covid-19 and Nafld (Non-alcoholic Fatty Liver Disease)mentioning

confidence: 99%

Risk of New-Onset Liver Injuries Due to COVID-19 in Preexisting Hepatic Conditions—Review of the Literature

Bucurica

Radu²,

Bucurica³

et al. 2022

Medicina

View full text Add to dashboard Cite

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) impacted the world and caused the 2019 coronavirus disease (COVID-19) pandemic. The clinical manifestations of the virus can vary from patient to patient, depending on their respective immune system and comorbidities. SARS-CoV-2 can affect patients through two mechanisms: directly by targeting specific receptors or by systemic mechanisms. We reviewed data in the latest literature in order to discuss and determine the risk of new-onset liver injuries due to COVID-19 in preexisting hepatic conditions. The particular expression of angiotensin-converting enzyme 2 (ACE2) receptors is an additional risk factor for patients with liver disease. COVID-19 causes more severe forms in patients with non-alcoholic fatty liver disease (NAFLD), increases the risk of cirrhosis decompensation, and doubles the mortality for these patients. The coinfection SARS-CoV-2—viral hepatitis B or C might have different outcomes depending on the stage of the liver disease. Furthermore, the immunosuppressant treatment administered for COVID-19 might reactivate the hepatic virus. The high affinity of SARS-CoV-2 spike proteins for cholangiocytes results in a particular type of secondary sclerosing cholangitis. The impact of COVID-19 infection on chronic liver disease patients is significant, especially in cirrhosis, influencing the prognosis and outcome of these patients.

show abstract

“…No se ha demostrado claramente el mismo papel en los pacientes con hígado graso metabólico (en los que predominan factores de riesgo como obesidad y diabetes), hepatitis viral, hepatitis autoinmune o enfermedades colestásicas. Las terapias antivirales pueden iniciarse y continuarse teniendo en cuenta el riesgo de reactivación con medicamentos inmunosupresores (17,18,19) .…”

unclassified

COVID 19 y enfermedad hepática: un panorama que está siendo aclarado

Quiróz

2022

Rev. colomb. Gastroenterol.

View full text Add to dashboard Cite

The Impact of Nonalcoholic Fatty Liver Disease on the Outcomes of Coronavirus Disease 2019 Infection

Abstract: Content available: Audio Recording

Cited by 5 publications

References 18 publications

Hepatic manifestations of coronavirus disease 2019 infection: Clinical and laboratory perspective

Hepatic manifestations of coronavirus disease 2019 infection: Clinical and laboratory perspective

Risk of New-Onset Liver Injuries Due to COVID-19 in Preexisting Hepatic Conditions—Review of the Literature

COVID 19 y enfermedad hepática: un panorama que está siendo aclarado

Contact Info

Product

Resources

About